Prosecution Insights
Last updated: May 29, 2026

Omeros Corporation

6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
6
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
0
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (33%)
2
Easy (33%)
2
Unknown (33%)

Rejection Statute Mix

BucketCases
§103 only2 (33%)
§112 only2 (33%)
No statute on record2 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SKELDING, ZACHARY S 2 59.9% +41.5%
WEN, SHARON X 1 56.5% +32.8%
PAK, MICHAEL D 1 58.2% +30.6%
KIM, YUNSOO 1 65.6% +35.2%
VISHNYAKOVA, ELENA VLADIMIROVNA 1 59.3% +73.3%

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17823793 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS VISHNYAKOVA, ELENA VLADIMIROVNA 149d overdue
18152536 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation SKELDING, ZACHARY S 147d overdue
18176155 HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS KIM, YUNSOO 121d overdue
18451632 Methods and Compositions for Treating Cancer PAK, MICHAEL D 10d overdue
18523203 ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS WEN, SHARON X 33d
18168192 COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION SKELDING, ZACHARY S 33d

Top Art Units

Art UnitApps
1641 2
1644 2
1674 1
1691 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18523203 ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS WEN, SHARON X 1641 §112 Non-Final OA 33d Pending Nov 29, 2023
18451632 Methods and Compositions for Treating Cancer PAK, MICHAEL D 1674 §112 Non-Final OA 10d overdue Pending Aug 17, 2023
18176155 HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS KIM, YUNSOO 1641 Other Non-Final OA 121d overdue Pending Feb 28, 2023
18168192 COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION SKELDING, ZACHARY S 1644 Other Non-Final OA 33d Pending Feb 13, 2023
18152536 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation SKELDING, ZACHARY S 1644 §103 Non-Final OA 147d overdue Pending Jan 10, 2023
17823793 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS VISHNYAKOVA, ELENA VLADIMIROVNA 1691 §103 Non-Final OA 149d overdue Pending Aug 31, 2022

Managing Omeros Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month